Clinical trial · Interventional
Use of Tranexamic Acid in Reduction of Post-Op Complications in Mohs Micrographic Surgery
Local Injection of Tranexamic Acid May Reduce Bleeding, Injection Pain, and Other Post-op Complications During Mohs Micrographic Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Drug supply issues
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the use of locally injected tranexamic acid (TXA) under the skin during Mohs micrographic surgery for removal of skin cancers in patients on anticoagulation. TXA may be helpful in reducing bleeding and pain during surgery, and may also lead to fewer post-operative complications following surgery such as graft loss, specifically in patients on blood-thinners.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Skin Neoplasms | Skin Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lidocaine Epinephrine | Drug | — | UNRESOLVED |
| Tranexamic acid injection | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Tranexamic acid
- description
- The TXA group will receive 2% lidocaine with 1:100,000 epinephrine mixed 50/50 with 50mg/ml TXA (with 50% dilution, this will yield 1% lidocaine with 1:200,000 epi).
- interventionNames
- Drug: Tranexamic acid injection
- Drug: Lidocaine Epinephrine
- type
- ACTIVE_COMPARATOR
- label
- Control
- description
- The control group will use the routine local anesthetic of buffered 1% lidocaine with 1:200,000 epinephrine.
- interventionNames
- Drug: Lidocaine Epinephrine
Primary outcomes (1)
- measure
- Postoperative Complications
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Must be on systemic anticoagulation therapy (indirect or direct anticoagulants or anti-platelet agents) * Must be scheduled for Mohs surgery at the University of Massachusetts Department of Dermatology Exclusion Criteria: * History of hypercoaguable disorder (e.g. Factor V Leiden Deficiency) * History of deep vein thrombosis or pulmonary embolism * Systolic blood pressure greater than 200 on day of surgery * Known allergy to TXA * Currently taking systemic retinoids * Unable to consent * Pregnant women * Prisoners
References
Publications (2)
- BACKGROUNDZilinsky I, Barazani TB, Visentin D, Ahuja K, Martinowitz U, Haik J. Subcutaneous Injection of Tranexamic Acid to Reduce Bleeding During Dermatologic Surgery: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Dermatol Surg. 2019 Jun;45(6):759-767. doi: 10.1097/DSS.0000000000001786. PMID 30640775
- BACKGROUNDPoeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, Opperer M, Boettner F, Memtsoudis SG. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ. 2014 Aug 12;349:g4829. doi: 10.1136/bmj.g4829. PMID 25116268